12 Best Drug Stocks to Buy Right Now

Page 2 of 11

10. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Number of Hedge Fund Holders: 59

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now. On September 5, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $149 from $144 while keeping an Outperform rating on the shares.

The firm told investors in a research note that, according to its latest analysis of prescription trends, Crenessity’s strong launch is expected to continue, with the drug exceeding Q3 consensus estimates.

It added that shares look to have appreciated closer to fair value, which may point towards increasing near-term optimism.

The same day, Sean Laaman from Morgan Stanley also expressed bullish sentiments for Neurocrine Biosciences, Inc. (NASDAQ:NBIX), giving the stock a Buy rating with a $163 price target.

Currently, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has an analyst consensus of Strong Buy, with the stock’s median price target of $141.87 implying an upside of 19.83% from current levels.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company with a focus on neuroscience. It is involved in the research and development, sale, and commercialization of pharmaceuticals that treat neuroendocrine, neurological, and neuropsychiatric disorders.

The company’s product portfolio includes treatments for chorea associated with Huntington’s disease, tardive dyskinesia, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

Page 2 of 11